Keltie

Firm overview:

With a footprint across the UK and Ireland, Keltie represents clients ranging from startups to multinationals in patent filing and prosecution, as well as opposition and appeal proceedings. The practice has become a destination for artificial intelligence (AI), quantum computing, fintech and advanced engineering mandates, while also supporting ambitious technology projects. Long-term investment in emerging industries, coupled with a highly collaborative culture, enables the team to advise clients whose inventions sit at the forefront of scientific and technological development.

Team overview:

Keltie’s technical bench is well suited to clients working at the edge of emerging technology. Mark Richardson and Michael Moore are important names within the team, bringing strength across areas including electronics, digital technologies, and life sciences. Around them, specialists in engineering, software and biotechnology provide strategic prosecution and opposition advice to multinational corporations, scaling businesses and research-led organisations with global innovation programmes.

Moore has developed a strong reputation for European opposition and appeal work, particularly within life sciences and biotechnology. His ability to combine detailed technical analysis with commercially pragmatic advice has made him a trusted adviser to innovative businesses seeking robust and defensible patent protection across multiple jurisdictions.

Richardson’s practice spans artificial intelligence, telecommunications and advanced digital technologies. He advises on all stages of the patent process, including invention harvesting, drafting and prosecution, portfolio management and freedom-to-operate matters.

Key matters:

• Mastercard: Patent portfolio management, strategic advice and EPO prosecution

Keltie advises Mastercard on European patent prosecution, portfolio strategy and IP planning, helping secure stronger protection for blockchain, cryptography and digital payments technologies while improving grant rates before the European Patent Office.

• Recursion Pharmaceuticals: AI drug discovery patent strategy

Keltie supports Recursion Pharmaceuticals on patent portfolio development, invention harvesting and freedom-to-operate advice, helping protect AI-driven drug discovery technologies across a range of scientific fields and international markets.

• PHINIA: Global patent portfolio and hydrogen technology strategy

The team manages PHINIA’s global patent portfolio for advanced automotive and hydrogen fuel technologies, providing strategic prosecution, freedom-to-operate advice, engineer training and embedded IP support across its international R&D operations.

Clients:

Amphista Therapeutics, Celyad Oncology, Entocycle, Good Dog Food (Meatly), Intelligent Energy, Mastercard, NBCUniversal, NEOM, Nissan Technical Centre Europe, PHINIA, Recursion Pharmaceuticals, Stryker, Subsea 7, Vestas Wind Systems, Zoom Communications